A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
← catalyst calendarNCT07213817 · readout in 803 d
Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
114estimated
Sites
12
Countries
France, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-05 | actual | When the study began enrolling |
| Primary completion | 2028-10-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-10-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-30 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Locally Advanced Solid Tumor
- Metastatic Solid Tumor
Intervention
- Biological: IPN60300
Primary outcomes
what the primary-completion date above is the date OFPhase Ia: Percentage of participants with dose limiting toxicity (DLT)
measured within 21 days following study drug administration.
Phase Ia and Ib: Percentage of participants experiencing Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TE SAEs).
measured From the first IPN60300 administration until 30 days after the last dose
Phase Ib: Objective response rate (ORR)
measured At end of study (up to approximately 3 years )
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed